Maxim Group disclosed Cellular Biomedicine (UNKNOWN:CBMG), hiking its price target to $16.00 earlier today
- Updated: September 21, 2016
Yesterday Cellular Biomedicine (UNKNOWN:CBMG) traded 0.35% higher at $14.33. The company’s 50-day moving average is $14.17 and its 200-day moving average is $15.40. The last stock close price is down -6.97% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 14,541 shares of the stock were exchanged, down from an average trading volume of 33,016
Reporting as possible upside of 0.12%, Maxim Group bumped up the target price of Cellular Biomedicine (UNKNOWN:CBMG) to $16.00
See Chart Below
Cellular Biomedicine has a 52 week low of $10.44 and a 52 week high of $25.20 The company’s market cap is currently $0.
About Cellular Biomedicine (UNKNOWN:CBMG)
Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company's technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.